Sfoglia per AUTORE
PERRINO M
Collezione AOU Alessandria
Items : 3
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma. in ESMO open / ESMO Open. 2022 Dec;7(6):100644. doi: 10.1016/j.esmoop.2022.100644. Epub 2022 Dec 1.
2022
AOU Alessandria
AOU Alessandria
Canova S; Ceresoli GL; Grosso F; Zucali PA; Gelsomino F; Pasello G; Mencoboni M; Rulli E; Galli F; De Simone I; Carlucci L; De Angelis A; Belletti M; Bonomi M; D'Aveni A; Perrino M; Bono F; Cortinovis DL;
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Oct;22(10):1438-1447. doi: 10.1016/S1470-2045(21)00404-6. Epub 2021 Sep 6.
2021
AOU Alessandria
AOU Alessandria
Pinto C; Zucali PA; Pagano M; Grosso F; Pasello G; Garassino MC; Tiseo M; Soto Parra H; Grossi F; Cappuzzo F; de Marinis F; Pedrazzoli P; Bonomi M; Gianoncelli L; Perrino M; Santoro A; Zanelli F; Bonelli C; Maconi A; Frega S; Gervasi E; Boni L; Ceresoli GL;
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16). in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2020 Apr;31(4):495-500. doi: 10.1016/j.annonc.2019.12.009. Epub 2020 Jan 16.
2020
AOU Alessandria
AOU Alessandria
Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;